Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1987 Sep;56(3):371–375. doi: 10.1038/bjc.1987.205

The reactivity of alpha-1-antitrypsin with Lens culinaris agglutinin and its usefulness in the diagnosis of neoplastic diseases of the liver.

C Sekine 1, Y Aoyagi 1, Y Suzuki 1, F Ichida 1
PMCID: PMC2002189  PMID: 2822074

Abstract

The reactivity of alpha-1-antitrypsin (AAT) with Lens culinaris agglutinin (LCA) was studied by crossed immuno-affinity electrophoresis of the sera of 246 subjects from 6 groups (acute virus hepatitis, chronic hepatitis, liver cirrhosis, hepatocellular carcinoma (HCC), carcinoma metastatic to the liver and normal controls). Two species of AAT (LCA-reactive and -nonreactive species) were detected on crossed immuno-affinity electrophoresis in a gel containing LCA. The percentages of LCA-reactive species of AAT in neoplastic diseases of the liver were significantly higher than those in benign liver diseases and normal controls. There was no correlation between the percentage of LCA-reactive species of AAT and serum AAT concentration in any group. Furthermore, in studying 15 pairs of serum samples before and after the subsequent development of HCC, the percentage of LCA-reactive species of AAT after HCC occurrence was significantly higher than that before, although there was no statistically significant difference between the serum AAT concentration before and after development of the disease. The latter 15 patients were all of the normal protease inhibitor phenotype (PiMM) and no change in phenotype was observed before and after the development of HCC. The results indicate that measurement of the reactivity of AAT with LCA can be a useful marker for the diagnosis of HCC and carcinoma metastatic to the liver, especially when serum concentrations of alpha-foetoprotein or other tumour markers are within the normal ranges.

Full text

PDF
371

Images in this article

372Figure 1
on p.372
373Figure 2
on p.373

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aoyagi Y., Isemura M., Suzuki Y., Sekine C., Soga K., Ozaki T., Ichida F. Change in fucosylation of alpha-fetoprotein on malignant transformation of liver cells. Lancet. 1986 Jan 25;1(8474):210–210. doi: 10.1016/s0140-6736(86)90681-1. [DOI] [PubMed] [Google Scholar]
  2. Aoyagi Y., Isemura M., Yosizawa Z., Suzuki Y., Sekine C., Ono T., Ichida F. Fucosylation of serum alpha-fetoprotein in patients with primary hepatocellular carcinoma. Biochim Biophys Acta. 1985 Aug 23;830(3):217–223. doi: 10.1016/0167-4838(85)90277-8. [DOI] [PubMed] [Google Scholar]
  3. Aoyagi Y., Suzuki Y., Isemura M., Soga K., Ozaki T., Ichida T., Inoue K., Sasaki H., Ichida F. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gan. 1984 Sep;75(9):809–815. [PubMed] [Google Scholar]
  4. Arnaud P., Wilson G. B., Koistinen J., Fudenberg H. H. Immunofixation after electrofocusing: improved method for specific detection of serum proteins with determination of isoelectric points. I. Immunofixation print technique for detection of alpha-1-protease inhibitor. J Immunol Methods. 1977;16(3):221–231. doi: 10.1016/0022-1759(77)90200-9. [DOI] [PubMed] [Google Scholar]
  5. Berg N. O., Eriksson S. Liver disease in adults with alpha-1 -antitrypsin deficiency. N Engl J Med. 1972 Dec 21;287(25):1264–1267. doi: 10.1056/NEJM197212212872502. [DOI] [PubMed] [Google Scholar]
  6. Bog-Hansen T. C. Crossed immuno-affinoelectrophoresis. An analytical method to predict the result of affinity chromatography. Anal Biochem. 1973 Dec;56(2):480–488. doi: 10.1016/0003-2697(73)90215-7. [DOI] [PubMed] [Google Scholar]
  7. Carrell R. W., Jeppsson J. O., Laurell C. B., Brennan S. O., Owen M. C., Vaughan L., Boswell D. R. Structure and variation of human alpha 1-antitrypsin. Nature. 1982 Jul 22;298(5872):329–334. doi: 10.1038/298329a0. [DOI] [PubMed] [Google Scholar]
  8. Eriksson S., Hägerstrand I. Cirrhosis and malignant hepatoma in alpha 1-antitrypsin deficiency. Acta Med Scand. 1974 Jun;195(6):451–458. doi: 10.1111/j.0954-6820.1974.tb08170.x. [DOI] [PubMed] [Google Scholar]
  9. Mega T., Lujan E., Yoshida A. Studies on the oligosaccharide chains of human alpha 1-protease inhibitor. II. Structure of oligosaccharides. J Biol Chem. 1980 May 10;255(9):4057–4061. [PubMed] [Google Scholar]
  10. Ordóez N. G., Manning J. T., Jr Comparison of alpha-1-antitrypsin and alpha-1-antichymotrypsin in hepatocellular carcinoma: an immunoperoxidase study. Am J Gastroenterol. 1984 Dec;79(12):959–963. [PubMed] [Google Scholar]
  11. Palmer P. E., Ucci A. A., Wolfe H. J. Expression of protein markers in malignant hepatoma: evidence for genetic and epigenetic mechanisms. Cancer. 1980 Mar 15;45(6):1424–1431. doi: 10.1002/1097-0142(19800315)45:6<1424::aid-cncr2820450621>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  12. Palmer P. E., Wolfe H. J. Alpha-antitrypsin deposition in primary hepatic carcinomas. Arch Pathol Lab Med. 1976 May;100(5):232–236. [PubMed] [Google Scholar]
  13. Sharp H. L., Bridges R. A., Krivit W., Freier E. F. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med. 1969 Jun;73(6):934–939. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES